Precision CRISPR: Drug Discovery and Gene Therapy

Memo

Precision CRISPR: Drug Development and Gene Therapy Congress returns for the 3rd time, just in time to face the building excitement in getting CRISPR gene therapy into the clinic. Take a look at the conference program and engage with this community today: https://bit.ly/2zdRx77    Through a dynamic program of focused sessions, interactive discussions and networking opportunities, you will leave this meeting with a deep understanding of: - the challenges in delivery and reducing off-target effects in ex vivo and in vivo gene therapies - how the likes of GSK, Novartis, AstraZeneca and more, work towards improving the efficacy of functional screening and drug discovery - the most recent gene editing techniques and Cas variants poised to make precise gene editing all that more precise   Preview Agenda Highlights: • Discover how to detect in vitro and ex vivo cellular indel profiles and dynamics induced by different CRISPR/Cas9 delivery formats with insights from Eric Paul Bennett, University of Copenhagen • Explore how Jacob Corn, ETH Zurich is forwarding gene repair in Human Hematopoietic Stem Cells and progressing towards translation of gene editing therapies for sickle cell disease • Find out how Barry Rosen, VP, AstraZeneca is utilising precise genome engineering to empower drug discovery   To find out more, get your event program here: https://bit.ly/2zdRx77 URLs:Brochure: https://go.evvnt.com/247589-0?pid=5569       Tickets: https://go.evvnt.com/247589-2?pid=5569  Time: 08:00 to 17:00. Venue details: The Hilton London Olympia, 380 Kensington High St, Kensington, London, W14 8N, United Kingdom. Speakers: Jacob Corn, Professor, UZH, Fredrik Wermeling, Assistant Professor, Karolinska Institute , Eric Paul Bennett, Associate Professor, University of Copenhagen, Andrew Bassett, Head of Research (Cellular Operations), Wellcome Trust Sanger Institute, Quin Wills, Department Head, Cellular and Systems Genomics, Novo Nordisk Research Centre, Barry Rosen, VP and Senior Principal Scientist, AstraZeneca , Lorena Benedetti, Research Associate, KCL and The Francis Crick Institute